Abstract
The trypanosome Trypanosoma brucei gambiense (Tbg) is a cause of human African trypanosomiasis (HAT) endemic to many parts of sub-Saharan Africa. The disease is almost invariably fatal if untreated and there is no vaccine, which makes monitoring and managing drug resistance highly relevant. A recent study of HAT cases from the Democratic Republic of the Congo reported a high incidence of relapses in patients treated with melarsoprol. Of the 19 Tbg strains isolated from patients enrolled in this study, four pairs were obtained from the same patient before treatment and after relapse. We used whole genome sequencing to investigate whether these patients were infected with a new strain, or if the original strain had regrown to pathogenic levels. Clustering analysis of 5938 single nucleotide polymorphisms supports the hypothesis of regrowth of the original strain, as we found that strains isolated before and after treatment from the same patient were more similar to each other than to other isolates. We also identified 23 novel genes that could affect melarsoprol sensitivity, representing a promising new set of targets for future functional studies. This work exemplifies the utility of using evolutionary approaches to provide novel insights and tools for disease control.
Highlights
Human African trypanosomiasis (HAT), known as sleeping sickness, is endemic in many parts of sub-Saharan Africa
All the clinical Trypanosoma brucei gambiense (Tbg) samples came from the cryobank of the World Health Collaboration Center for Research and Training on Human African Trypanosomiasis Diagnostics and originated from patients enrolled in a longitudinal study of HAT at Dipumba Hospital in Mbuji-Mayi, DRC
To summarize the methods found in these studies, blood or cerebrospinal fluid (CSF) containing trypanosomes was taken from the patient when they were first admitted, before treatment (BT)
Summary
Human African trypanosomiasis (HAT), known as sleeping sickness, is endemic in many parts of sub-Saharan Africa. The recommended first line therapy for late-stage gambiense HAT is a combination of nifurtimox and eflornithine (Priotto et al 2009; Simarro et al 2012). These drugs are less toxic than melarsoprol, this combination therapy (NECT) is difficult to administer (Simarro et al 2012), and resistance might soon be an issue, as up to 2% of cases relapse after NECT treatment (Franco et al 2012)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.